SGRYSurgery Partners, Inc.
Is it safe?
Mostly sound, with a caveat: insiders buying, but heavy debt (BB) and big price swings.
Insiders were net buyers (+$161K, 90 days to Oct 22, 2026). SEC Form 4 filings: officers and directors must report their own trades within two business days.
Moderately leveraged. A rule of thumb on leverage, not a credit rating.
Large price swings, high volatility. Worst drawdown -83% · now 31% below its 52-week high.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can SGRY take a bad year?
Surgery Partners, Inc. carries $3.53B of net debt at 6.30× EBITDA: a heavy load to carry through a bad year.
Net debt · as at Q2 2026 · over four years of earnings before interest, tax and depreciation, heavy
- Net debt / EBITDA
- 6.30×
Net debt / EBITDA · 6.37× a year ago · the load is coming down
- Debt / equity
- 2.25×
Debt / equity
- Annualised volatility
- 49%
Annualised volatility · S&P 500 16% · about 3 times the market's own swing
Details›
- Total debtQ2 2026
- $3.75B
- Cash and short-term investments
- $217M
- Net debt
- $3.53B
- EBITDA, trailing twelve months
- $561M
- Operating profit, trailing twelve months
- $384M
- Debt / equity
- 2.25×
- Total debt / EBITDA
- 6.69×
- Annualised volatilitytwo years of daily moves
- 49%
- Worst drawdown on file
- −83%
- Below its 52-week high
- 31%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.
The balance sheet
What it owes against what it owns, and how close that comes to trouble.
How far can it fall?
How much the price moves, how deep and how long its falls have run, and what each unit of risk has paid.